Kairos Therapeutics

Kairos Therapeutics is a biopharmaceutical company with a proprietary next-generation antibody-drug conjugate platform based on novel toxin, linker, and site-specific conjugation technology.

This technology enables the development of highly efficacious and targeted therapeutics with reduced side-effects. Through key partnerships, Kairos is developing a pipeline of novel antibody-drug conjugate therapeutics for the treatment of multiple forms of cancer.